Pharmaceuticals
The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan
HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao,Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, indust...
2023-11-03 12:10
837
ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaft...
2023-11-03 09:15
818
ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting
SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the ...
2023-11-03 09:10
719
PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...
2023-11-03 05:15
614
Lion TCR clinched the prestigious T-Up Excellence Awards in Singapore
SINGAPORE, Nov. 2, 2023 /PRNewswire/ -- At the annual Singapore Week of Innovation and Technology (SWITCH) 2023, Lion TCR, a clinical-stage mRNA-based T cell immunotherapy company, is thrilled to announce a significant milestoneof clinching the T-Up Excellence Awards. This award, in recognitio...
2023-11-02 20:41
2219
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio * I-Mab has full development and commercialization rights of felzartamab in Greater China for all indications, with Phase 3 multiple myelom...
2023-11-02 20:00
1167
Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...
2023-11-02 20:00
726
European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC)
- BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC - The application is based on results from the PHAROS study,[1] which showed an objective response rate of 75% in treatment-naïve patients and 46% in previou...
2023-11-02 18:52
933
Cambrex Announces Sale of Drug Product Business Unit
EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit toWilmington, Delaware based Noramco. Cambrex's Drug Product business provides product developme...
2023-11-02 18:00
1554
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") thro...
2023-11-02 15:58
1491
Xinhua Silk Road: 54th Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi
BEIJING, Nov. 2, 2023 /PRNewswire/ -- The 54th Zhangshu National Traditional
Chinese Materia Medica Trade Fair was held recently in Zhangshu, a county-level
city in eastChina's Jiangxi Province.
2023-11-02 14:21
2327
TraceLink MINT Wins 2023 Pharma Innovation Award: 100% End-to-End Supply Chain Digitalization is Now Within Reach
100% End-to-End Supply Chain Digitalization is Now Possible with Proven Network Orchestration Capability BOSTON, Nov. 2, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life...
2023-11-02 05:22
1801
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Clinical Dermatology Conference HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Nov. 1, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries,...
2023-11-01 22:07
2279
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunother...
2023-11-01 20:00
1616
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainlandChina. CStone to retain the rights to nofazinlimab outside mainland China. * This partnership will combine the strengths of CStone a...
2023-11-01 18:10
3464
Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
LONDON, Nov. 1, 2023 /PRNewswire/ -- Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be ...
2023-11-01 09:05
1099
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2023-11-01 08:30
1640
BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ Ventures
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the deve...
2023-10-31 21:00
3399
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-31 20:30
1546
Meihua International Medical Technologies Co., Ltd. Establishes A Subsidiary Dedicated to Introducing International Patented Pharmaceuticals and Medical Device Technologies to China and Hainan Free Trade Port Boao Hope City
YANGZHOU, China, Oct. 31, 2023 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, announced today the establishme...
2023-10-31 20:00
2824
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 302 media titles]
2025-01-23 09:00
Agoda Expands Its Eco Deals Program Pledging Up to $1.5 Million to Fund Critical Conservation Projects Across 10 Asian Markets in Partnership with WWF
[Picked up by 292 media titles]
2025-01-23 09:00
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
7768
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
5664
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4964
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
4801
